Pharmacogenomic Testing to Guide Treatment of Major Depressive Disorder: A Systematic Review
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
1 Online-Ressource.
- Language
-
Englisch
- Bibliographic citation
-
Pharmacogenomic Testing to Guide Treatment of Major Depressive Disorder: A Systematic Review ; volume:11 ; number:2 ; day:31 ; month:5 ; year:2024 ; pages:123-140 ; date:6.2024
Current treatment options in psychiatry ; 11, Heft 2 (31.5.2024), 123-140, 6.2024
- Creator
-
Khorassani, Farah
Jermain, Mandy
Cadiz, Christine
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s40501-024-00316-x
- URN
-
urn:nbn:de:101:1-2409230947417.591402939895
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:20 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Khorassani, Farah
- Jermain, Mandy
- Cadiz, Christine
- SpringerLink (Online service)
Other Objects (12)
Reply to Sun: Dynamic and accessible pharmacogenomic results: a response to pharmacogenomic testing for antidepressant treatment selection
Pharmacogenomic testing for antidepressant treatment selection: lessons learned and roadmap forward
The use of esketamine in comorbid treatment resistant depression and obsessive compulsive disorder following extensive pharmacogenomic testing: a case report
Investigation of community pharmacists’ knowledge and attitudes of pharmacogenomics testing: implication for improved pharmacogenomic testing practice
Potential pharmacogenomic targets in bipolar disorder: considerations for current testing and the development of decision support tools to individualize treatment selection
Designing an evidence based community pharmacy service specification for a pharmacogenomic testing service
Temperament and major depressive disorder
Postpartum Depressive Disorder – Psychosomatic Aspects
Clinical validation of a combinatorial PharmAcogeNomic approach in major Depressive disorder: an Observational prospective RAndomized, participant and rater-blinded, controlled trial (PANDORA trial)
Comprehensive pharmacogenomic characterization of gastric cancer
Brain aging in major depressive disorder : results from the ENIGMA major depressive disorder working group
Chipping away at major depressive disorder
Reply to Sun: Dynamic and accessible pharmacogenomic results: a response to pharmacogenomic testing for antidepressant treatment selection
Pharmacogenomic testing for antidepressant treatment selection: lessons learned and roadmap forward
The use of esketamine in comorbid treatment resistant depression and obsessive compulsive disorder following extensive pharmacogenomic testing: a case report
Investigation of community pharmacists’ knowledge and attitudes of pharmacogenomics testing: implication for improved pharmacogenomic testing practice
Potential pharmacogenomic targets in bipolar disorder: considerations for current testing and the development of decision support tools to individualize treatment selection
Designing an evidence based community pharmacy service specification for a pharmacogenomic testing service
Temperament and major depressive disorder
Postpartum Depressive Disorder – Psychosomatic Aspects
Clinical validation of a combinatorial PharmAcogeNomic approach in major Depressive disorder: an Observational prospective RAndomized, participant and rater-blinded, controlled trial (PANDORA trial)
Comprehensive pharmacogenomic characterization of gastric cancer
Brain aging in major depressive disorder : results from the ENIGMA major depressive disorder working group
Chipping away at major depressive disorder
Reply to Sun: Dynamic and accessible pharmacogenomic results: a response to pharmacogenomic testing for antidepressant treatment selection
Pharmacogenomic testing for antidepressant treatment selection: lessons learned and roadmap forward
The use of esketamine in comorbid treatment resistant depression and obsessive compulsive disorder following extensive pharmacogenomic testing: a case report
Investigation of community pharmacists’ knowledge and attitudes of pharmacogenomics testing: implication for improved pharmacogenomic testing practice
Potential pharmacogenomic targets in bipolar disorder: considerations for current testing and the development of decision support tools to individualize treatment selection
Designing an evidence based community pharmacy service specification for a pharmacogenomic testing service
Temperament and major depressive disorder
Postpartum Depressive Disorder – Psychosomatic Aspects
Clinical validation of a combinatorial PharmAcogeNomic approach in major Depressive disorder: an Observational prospective RAndomized, participant and rater-blinded, controlled trial (PANDORA trial)
Comprehensive pharmacogenomic characterization of gastric cancer
Brain aging in major depressive disorder : results from the ENIGMA major depressive disorder working group